Agilent Expands into Clinical NGS with CE-IVD-Labeled TapeStationDx Systems
Event summary
- Agilent launched the 4150 and 4200 TapeStationDx systems and accompanying software for clinical NGS sample quality control.
- The systems are CE-IVD-labeled, designed for regulated clinical laboratory environments.
- The 4150 system supports 1-16 samples, while the 4200 system scales to 96 samples.
- Both systems deliver automated sample quality control in 1-2 minutes per sample.
- The software includes data integrity features like audit trails and electronic signatures.
The big picture
Agilent's launch of the TapeStationDx systems marks its entry into the regulated clinical NGS space, addressing the growing demand for standardized and traceable sample quality control. The move aligns with the expansion of clinical NGS and increasing regulatory expectations, such as the IVDR in Europe. With revenue of $6.95 billion in fiscal year 2025, Agilent is leveraging its established TapeStation technology to support clinical laboratories in delivering accurate and timely genomic information for patient care.
What we're watching
- Market Adoption
- The pace at which clinical laboratories in the U.S., Canada, and Europe will integrate the TapeStationDx systems into their workflows.
- Regulatory Compliance
- Whether Agilent can sustain its lead in offering CE-IVD-labeled solutions as clinical NGS regulatory expectations evolve.
- Competitive Dynamics
- How this expansion will position Agilent against competitors in the clinical NGS sample quality control market.
Related topics